Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC3 | Q13507 | 4/20 | 0.35 |
| ▸ | TRPC6 | Q9Y210 | 4/20 | 0.35 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21522981 | 0.88 | TRPC3 (0.35) | TRPC3TRPC6TNIKTRPA1CACNA1C | |
| SCHEMBL19685037 | 0.88 | TNIK (0.31) | TNIK | |
| SCHEMBL31438347 | 0.88 | TRPC3 (0.35) | TRPC3TRPC6TNIKTRPA1CACNA1C | |
| SCHEMBL31438379 | 0.88 | TRPC3 (0.35) | TRPC3TRPC6TNIKTRPA1CACNA1C | |
| SCHEMBL19668008 | 0.86 | TRPC3 (0.33) | TRPC3TRPC6TNIK | |
| SCHEMBL31438409 | 0.86 | TRPC3 (0.35) | TRPC3TRPC6TNIKTRPA1CACNA1C | |
| SCHEMBL31438406 | 0.86 | TRPC3 (0.35) | TRPC3TRPC6TNIKTRPA1CACNA1C | |
| SCHEMBL19685090 | 0.80 | TNIK (0.35) | TNIK | |
| SCHEMBL31438354 | 0.80 | TRPC3 (0.35) | TRPC3TRPC6TNIKTRPA1CACNA1C | |
| SCHEMBL31438348 | 0.80 | TRPC3 (0.35) | TRPC3TRPC6TNIKTRPA1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109195966-B | Microbiocidal thiazole derivatives | 先正达参股股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
| EP-3464284-B1 | MICROBIOCIDAL THIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-10-21 | — | — | EP | disclosed |
| EP-3464284-B1 | MICROBIOCIDAL THIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-10-21 | — | — | EP | disclosed |
| US-20200277288-A1 | Microbiocidal Thiazole Derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-09-03 | — | — | US | disclosed |
| US-10662182-B2 | Microbiocidal thiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| US-10662182-B2 | Microbiocidal thiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| US-20190330168-A1 | MICROBIOCIDAL THIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-10-31 | — | — | US | disclosed |
| US-20190330168-A1 | MICROBIOCIDAL THIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-10-31 | — | — | US | disclosed |
| WO-2017207362-A1 | MICROBIOCIDAL THIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277288-A1 | Microbiocidal Thiazole Derivatives | MSR1, CASP1, TLR1 | TRPC3 912/4885TRPC6 1955/4885TNIK 3706/4885 |
| US-20190330168-A1 | MICROBIOCIDAL THIAZOLE DERIVATIVES | MSR1, CASP1, MPO | TRPC3 874/4885TRPC6 1900/4885TNIK 3730/4885 |
| US-10662182-B2 | Microbiocidal thiazole derivatives | MSR1, CASP1, MPO | TRPC3 874/4885TRPC6 1900/4885TNIK 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.